Comparing neostigmine and metoclopramide on gastric residual volume

Phase 3

Recruiting

• Conditions: dilatation of volume.; Acute dilatation of stomach; K31.0

• Registration Number: IRCT20190804044432N1
• Lead Sponsor: Zahedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 October 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Age between 20 and 50 years
Patients under mechanical ventilation
Patients with enteral nutrition through nasogastric tube

Exclusion Criteria

Previous use of beta blockers
Heart Block
Bradycardia (heart rate less than 60) before inclusion
Hypothermia in the form of central temperature below 35 degrees
Kidney Failure (CR> 1.5)
Use Erythromycin or Cisapride within 8 hours before starting the study
Recent surgery on stomach or digestive tract within the last ten days
Signs and symptoms of bowel obstruction
Pregnancy and lactation
Active bronchospasm
Extrapyramidal symptoms
Sensitivity to Neostigmine
Active gastrointestinal bleeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Gastric residual volume. Timepoint: Before starting the drug infusion and 3, 6, 9 and 12 hours after the start of the infusion. Method of measurement: Aspirate with a gavage syringe.